COVID-19COVIDENCE UKNCT04330599

Longitudinal Population-based Observational Study of COVID-19 in the UK Population

An observational study of COVID-19, run by Queen Mary University of London at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

COVIDENCE UK is a population-based observational longitudinal study that has the following objectives: 1. To determine risk factors for incident COVID-19 and for adverse outcomes of COVID-19 in the UK population 2. To characterise the natural history of COVID-19 in the UK population 3. Read more about this study

Who is it for?: Ages 16 years and olderHealthy volunteers can take part
Conditions the study is for: COVID-19
How many people: 19,981 participants
Where: 1 siteUnited Kingdom
Study dates: 27 Apr 2020to 27 Jul 2026
Phase: Observational
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 16 years and older
All sexes
Healthy volunteers accepted
Child, Adult, Older adult

Study population: UK residents aged 16 years or more

Who may be able to join

UK resident
Age ≥16 years

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site

Queen Mary University of London
London, County (optional), E1 2AB

Other trials in United Kingdom

About this study

COVIDENCE UK is a population-based observational longitudinal study that has the following objectives:

To determine risk factors for incident COVID-19 and for adverse outcomes of COVID-19 in the UK population
To characterise the natural history of COVID-19 in the UK population
To evaluate the impact of COVID-19 on the physical and mental health of the UK population
To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in COVIDENCE as comparison or control data for trial participants who have been randomised to receive one or more interventions.

Conditions: COVID-19
Medical subject headings: COVID-19

What is being measured

The primary outcome is the main question the study is designed to answer.

Incidence of confirmed COVID-19
Measured: 5 years

Secondary outcomes (14)

Incidence of probable or suspected COVID-19
Measured: 5 years
Incidence of COVID-19 requiring hospitalisation
Measured: 5 years
Incidence of COVID-19 requiring ventilatory support
Measured: 5 years
Incidence of fatal COVID-19
Measured: 5 years
Symptom duration per COVID-19 episode
Measured: 5 years
Symptom severity per COVID-19 episode
Measured: 5 years
Incidence of seroconversion to SARS-CoV-2
Measured: 5 years
Incidence of recurrent COVID-19
Measured: 5 years
EQ-5D-3L health-related quality of life score
Measured: 5 years
Health care costs associated with incident COVID-19
Measured: 5 years
Impact of the COVID-19 pandemic and the societal response on participants' financial status
Measured: 5 years
Incidence of COVID-19 on participant's physical health
Measured: 5 years
Impact of COVID-19 on participants' mental health
Measured: 5 years
Impact of COVID-19 on physical health of offspring born to participants during follow-up
Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

27 Apr 202027 Jul 2026

First posted1 Apr 2020
Study start27 Apr 2020
Primary completion27 Jul 2026
Study completion27 Jul 2026

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (5)Papers the sponsor has linked to this study.
Other trials for COVID-19Studies of the same condition, open and under way.
More trials run by Queen Mary University of LondonThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Cohort
Time perspective: Prospective
Enrolment: 19,981 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT04330599
Sponsor's protocol ID: COVIDENCE UK
Acronym: COVIDENCE UK
Status last verified: Oct 2026
First submitted: 31 Mar 2020
Last updated: 2 Nov 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes

Publications

Vivaldi G, Talaei M, Blaikley J, Jackson C, Pfeffer PE, Shaheen SO, Martineau AR. Bidirectional relationship between sleep problems and long COVID: a longitudinal analysis of data from the COVIDENCE UK study. BMJ Open Respir Res. 2025 Jun 15;12(1):e002506. doi: 10.1136/bmjresp-2024-002506.
PubMed 40518292
Vivaldi G, Pfeffer PE, Talaei M, Basera TJ, Shaheen SO, Martineau AR. Long-term symptom profiles after COVID-19 vs other acute respiratory infections: an analysis of data from the COVIDENCE UK study. EClinicalMedicine. 2023 Oct 6;65:102251. doi: 10.1016/j.eclinm.2023.102251. eCollection 2023 Nov.
PubMed 38106559
Tydeman F, Pfeffer PE, Vivaldi G, Holt H, Talaei M, Jolliffe D, Davies G, Lyons RA, Griffiths C, Kee F, Sheikh A, Shaheen SO, Martineau AR. Rebound in asthma exacerbations following relaxation of COVID-19 restrictions: a longitudinal population-based study (COVIDENCE UK). Thorax. 2023 Aug;78(8):752-759. doi: 10.1136/thorax-2022-219591. Epub 2022 Nov 23.
PubMed 36423925
Williamson AE, Tydeman F, Miners A, Pyper K, Martineau AR. Short-term and long-term impacts of COVID-19 on economic vulnerability: a population-based longitudinal study (COVIDENCE UK). BMJ Open. 2022 Aug 23;12(8):e065083. doi: 10.1136/bmjopen-2022-065083.
PubMed 35998959
Holt H, Talaei M, Greenig M, Zenner D, Symons J, Relton C, Young KS, Davies MR, Thompson KN, Ashman J, Rajpoot SS, Kayyale AA, El Rifai S, Lloyd PJ, Jolliffe D, Timmis O, Finer S, Iliodromiti S, Miners A, Hopkinson NS, Alam B, Lloyd-Jones G, Dietrich T, Chapple I, Pfeffer PE, McCoy D, Davies G, Lyons RA, Griffiths C, Kee F, Sheikh A, Breen G, Shaheen SO, Martineau AR. Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK). Thorax. 2022 Sep;77(9):900-912. doi: 10.1136/thoraxjnl-2021-217487. Epub 2021 Nov 30.
PubMed 34848555

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
RecruitingPhase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Coronavirus Disease (COVID-19)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19

All COVID-19 trials

Study at a glance

From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Longitudinal Population-based Observational Study of COVID-19 in the UK Population
ClinicalTrials.gov ID: NCT04330599
Acronym / sponsor ID: COVIDENCE UK / COVIDENCE UK
Conditions: COVID-19
Study type: Observational
Recruitment status: Completed
Enrolment: 19,981 participants (actual)
Lead sponsor: Queen Mary University of LondonUniversity, hospital or other
Collaborators: King's College London, London School of Hygiene and Tropical Medicine, University of Edinburgh, Swansea University, Queen's University, Belfast, Barts & The London NHS Trust
Study start: 27 Apr 2020 (actual)
Primary completion: 27 Jul 2026 (actual)
Study completion: 27 Jul 2026 (actual)
First posted: 1 Apr 2020 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

COVIDENCE UK is a population-based observational longitudinal study that has the following objectives:

To determine risk factors for incident COVID-19 and for adverse outcomes of COVID-19 in the UK population
To characterise the natural history of COVID-19 in the UK population
To evaluate the impact of COVID-19 on the physical and mental health of the UK population
To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in COVIDENCE as comparison or control data for trial participants who have been randomised to receive one or more interventions.

Study design

Observational model: Cohort
Time perspective: Prospective

Who may qualify

Ages: 16 years and older
Sex: All
Healthy volunteers: Accepted
Age groups: Child, Adult, Older adult
Study population: UK residents aged 16 years or more

Key inclusion criteria (2 listed)

UK resident
Age ≥16 years

Key exclusion criteria (0 listed)

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Primary outcome

Incidence of confirmed COVID-19
Time frame: 5 years

14 secondary outcomes

Incidence of probable or suspected COVID-19
Time frame: 5 years
Incidence of COVID-19 requiring hospitalisation
Time frame: 5 years
Incidence of COVID-19 requiring ventilatory support
Time frame: 5 years
Incidence of fatal COVID-19
Time frame: 5 years
Symptom duration per COVID-19 episode
Time frame: 5 years
Symptom severity per COVID-19 episode
Time frame: 5 years
Incidence of seroconversion to SARS-CoV-2
Time frame: 5 years
Incidence of recurrent COVID-19
Time frame: 5 years
EQ-5D-3L health-related quality of life score
Time frame: 5 years
Health care costs associated with incident COVID-19
Time frame: 5 years
Impact of the COVID-19 pandemic and the societal response on participants' financial status
Time frame: 5 years
Incidence of COVID-19 on participant's physical health
Time frame: 5 years
Impact of COVID-19 on participants' mental health
Time frame: 5 years
Impact of COVID-19 on physical health of offspring born to participants during follow-up
Time frame: 5 years

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
Derived from this study: PubMed 40518292Vivaldi G, Talaei M, Blaikley J, Jackson C, Pfeffer PE, Shaheen SO, Martineau AR. Bidirectional relationship between sleep problems and long COVID: a longitudinal analysis of data from the COVIDENCE UK study. BMJ Open Respir Res. 2025 Jun 15;12(1):e002506. doi: 10.1136/bmjresp-2024-002506.
Derived from this study: PubMed 38106559Vivaldi G, Pfeffer PE, Talaei M, Basera TJ, Shaheen SO, Martineau AR. Long-term symptom profiles after COVID-19 vs other acute respiratory infections: an analysis of data from the COVIDENCE UK study. EClinicalMedicine. 2023 Oct 6;65:102251. doi: 10.1016/j.eclinm.2023.102251. eCollection 2023 Nov.
Derived from this study: PubMed 36423925Tydeman F, Pfeffer PE, Vivaldi G, Holt H, Talaei M, Jolliffe D, Davies G, Lyons RA, Griffiths C, Kee F, Sheikh A, Shaheen SO, Martineau AR. Rebound in asthma exacerbations following relaxation of COVID-19 restrictions: a longitudinal population-based study (COVIDENCE UK). Thorax. 2023 Aug;78(8):752-759. doi: 10.1136/thorax-2022-219591. Epub 2022 Nov 23.
Derived from this study: PubMed 35998959Williamson AE, Tydeman F, Miners A, Pyper K, Martineau AR. Short-term and long-term impacts of COVID-19 on economic vulnerability: a population-based longitudinal study (COVIDENCE UK). BMJ Open. 2022 Aug 23;12(8):e065083. doi: 10.1136/bmjopen-2022-065083.
Derived from this study: PubMed 34848555Holt H, Talaei M, Greenig M, Zenner D, Symons J, Relton C, Young KS, Davies MR, Thompson KN, Ashman J, Rajpoot SS, Kayyale AA, El Rifai S, Lloyd PJ, Jolliffe D, Timmis O, Finer S, Iliodromiti S, Miners A, Hopkinson NS, Alam B, Lloyd-Jones G, Dietrich T, Chapple I, Pfeffer PE, McCoy D, Davies G, Lyons RA, Griffiths C, Kee F, Sheikh A, Breen G, Shaheen SO, Martineau AR. Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK). Thorax. 2022 Sep;77(9):900-912. doi: 10.1136/thoraxjnl-2021-217487. Epub 2021 Nov 30.
Individual participant dataSharing planned: Yes

Related trials for COVID-19

Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
RecruitingPhase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Coronavirus Disease (COVID-19)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of COVID-19, run by Queen Mary University of London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of confirmed COVID-19 (time frame: 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04330599, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.